TNF-α receptor expression correlates with histologic activity of otosclerosis

Otology and Neurotology

Volumn 30, Issue 8, 2009, Pages 1131-1137

  Csomor, Péter ^a   Sziklai, István ^a   Karosi, Tamás ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Inflammation; Nonotosclerotic stapes fixation; Otosclerosis; Tumor necrosis factor ; Tumor necrosis factor receptors

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOLESCENT; ADULT; AGED; ANKYLOSIS; ARTICLE; BIOSYNTHESIS; CARTILAGE; CARTILAGE CELL; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; OTOSCLEROSIS; PATHOLOGY; PHYSIOLOGY; STAPES;

ADOLESCENT; ADULT; AGED; ANKYLOSIS; CARTILAGE; CHONDROCYTES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OTOSCLEROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STAPES; YOUNG ADULT;

EID: 74349086293     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e3181be6af4     Document Type: Article

References (30)

1. Chole RA, McKenna MJ. Patophysiology of otosclerosis. Otol Neurotol 2001;22:249-57.
2. Friedmann I. Pathology of the Ear. Oxford, UK: Blackwell Scientific Publications, 1974.
3. Iyer V, Gristwood H. Histopathology of the stapes in otosclerosis. Pathology 1984;16:30-8.
4. Cureoglu S, Schachern PA, Ferlito A, Rinaldo A, Tsuprun V, Paparella MM. Otosclerosis: etiopathogenesis and histopathology. Am J Otolaryngol 2006;27:334-40.
5. Arnold W, Niedermeyer HP, Lehn N, Neubert W, Höfler H. Measles virus in otosclerosis and the specific immune response of the inner ear. Acta Otolaryngol (Stockh) 1996;116:705-9.
6. McKenna MJ, Kristiansen AG, Haines J. Polymerase chain reaction amplification of measles virus sequence from human temporal bone sections with active otosclerosis. Am J Otol 1996;17: 827-30.
7. Karosi T, Kónya J, Szabó LZ, Sziklai I. Measles virus prevalence in otosclerotic stapes footplate samples. Otol Neurotol 2004;25: 451-6.
8. Karosi T, Jókay I, Kónya J, et al. Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic stapes footplates in connection with measles virus positivity. Laryngoscope 2006;116:1427-33.
9. Karosi T, Kónya J, Szabó LZ, et al. Codetection of measles virus and tumor necrosis factor-> mRNA in otosclerotic stapes footplates. Laryngoscope 2005;115:1291-7.
10. Mannel DN, Echtenacher B. TNF in the inflammatory response. Chem Immunol 2000;74:141-61.
11. Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A 1998;95:570-5.
12. Bazan JF. Emerging families of cytokines and receptors. Curr Biol 1993;3:603-6.
13. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001;104: 487-501.
14. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65.
15. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 2002;296:1634-5.
16. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988;53: 45-53.
17. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S, Peter ME. Apoptosis signaling by death receptors. Eur J Biochem 1998;254: 439-59.
18. Karosi T, Jókay I, Kónya J, et al. Activated osteoclasts with CD51/61 expression in otosclerosis. Laryngoscope 2006;116: 1478-84.
19. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001;13:164-9.
20. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor->, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope 2002;112:1627-34.
21. Cohen S, Shoup A, Weisman MH, Harris JP. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebocontrolled study. Otol Neurotol 2005;26:903-7.
22. Street I, Jobanputra P, Proops DW. Etanercept, a tumour necrosis factor > receptor antagonist, and methotrexate in acute sensorineural hearing loss. J Laryngol Otol 2006;120:1064-6.
23. Sziklai I. Human otosclerotic bone-derived peptide decreases the gain of the electromotility in isolated outer hair cells. Hear Res 1996;95:100-7.
24. Wang X, Truong T, Billings PB, Harris JP, Keithley EM. Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 2003;24:52-7.
25. Van Wijk F, Staecker H, Keithley E, Lefebvre PP. Local perfusion of the tumor necrosis factor > blocker infliximab to inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol 2006;11:357-65.
26. Zehnder AF, Kristiansen AG, Adams JC, Kujawa SG, Merchant SN, McKenna MJ. Osteoprotegrin knockout mice demonstrate abnormal remodeling of the otic capsule and progressive hearing loss. Laryngoscope 2006;116:201-6.
27. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodelling. Cytokine Growth Factor Rev 2004;15:457-75.
28. Brookler K. Medical treatment of otosclerosis: rationale for use of bisphosphonates. Int Tinnitus J 2008;14:92-6.
29. Brookler KH, Tanyeri H. Etidronate for the the neurotologic symptoms of otosclerosis: preliminary study. Ear Nose Throat J 1997; 76:371-6, 379-81.
30. Van Den Bogaert K, Govaerts PJ, De Leenheer EM, et al. Otosclerosis: a genetically heterogeneous disease involving at least three different genes. Bone 2002;30:624-30.